Navigation Links
Pharmos Corporation Reports 2009 Third Quarter Results
Date:11/12/2009

the Company's 2008 restructuring plans.

Other expense net, decreased by $58,162 from $83,859 in other expense in 2008 to $25,697 in other expense in 2009. The reduction is related to the decreased interest income of $42,285 from a decline in cash and cash equivalents offset by a $92,973 reduction in interest expense attributable to reduced debenture interest and a $7,474 decrease in translation gains and losses that were recorded at our Rehovot location. In the third quarter of 2009 the Company recorded $29,606 in interest expense related to the remaining of $1,000,000 in convertible debentures issued on January 3, 2008.

Nine-months Ended September 30, 2009

For the nine months ended September 30, 2009, Pharmos recorded a net loss of $7.3 million, or $0.16 per share compared to a net loss of $9.1 million, or $0.35 per share for the nine months ended September 30, 2008. Total operating expenses decreased 27% to $6.6 million from $9.0 million.

Research & development expenses decreased by $2,940,572 or 41% from $7,206,909 in 2008 to $4,266,337 in 2009, related to the Company's primary focus of cash resources on the Dextofisopam Phase 2b trial and the downsizing and curtailment of general research and development programs. The decline reflects decreases in virtually every research and development expense category. The primary reductions include a $724,000 reduction in payroll, a $327,000 reduction in consultant and professional fees, a $1,547,000 reduction in clinical studies and $342,000 reduction in various other areas. The decrease in these costs reflect the closing of the Rehovot facility effective October 31, 2008 and the fact that the Dextofisopam trial is complete.

In the first nine months of 2009, the Company completed a Phase 2b trial of its lead compound, Dextofisopam, in female IBS patients. The Phase 2b trial was fully enrolled on April 9, 2009 at 324 patients. Costs of $3,946,000 were inc
'/>"/>

SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmos Issues Business Update on Dextofisopam Trial and Financing
2. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
3. MedCath Corporation Reports Fourth Quarter Earnings
4. Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA
5. Dr. John Mills and Joseph Gentile Join Board of Directors of ChanTest Corporation
6. Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast
7. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
8. China National Medicines Corporation Issues Milestone Purchase Order for 12,000 STA Systems
9. China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou
10. MedCath Corporation to Hold Conference Call on Fourth Quarter Results
11. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... luglio 2014 ResMed (NYSE: RMD ... la cura dei disturbi respiratori del sonno (SDB) e ... permanente in Germania contro il produttore Taiwanese di dispositivi ... di apparecchiature da indossare in testa, che violano i ... 220. La sentenza della Corte Regionale Distrettuale di ...
(Date:7/28/2014)... OXFORD, England , July 28, 2014 ... bekannt, dass Albion Ventures 2,5 Millionen £ ... Kundenautomatisierungsmanagement in der Konsumgüter-, Gesundheits-, Pharma- und ... Shackleton Ventures.      (Photo: ... letzten 18 Monaten hat OmPrompt sein beschleunigtes ...
(Date:7/28/2014)... INCLINE VILLAGE, Nev. , July 28, 2014 ... announced that the Company will release its second quarter 2014 ... Monday, August 11, 2014, after market close. PDL,s management will ... p.m. Eastern Time to discuss the financial results.  A slide ... webcast link on the PDL website. Conference Call ...
Breaking Medicine Technology:ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2
... 2012  PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... March 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20111025/LA93174LOGO-c ... loss from continuing operations of $513,000, or $0.16 per ... compared to income from continuing operations of $909,000, or ...
... OAKS, Calif., May 4, 2012  Amgen (NASDAQ: AMGN ... Wednesday, May 9, 2012, at the Four Seasons Hotel, Chicago, ... vice president of Investor Relations at Amgen, will present. Live ... Calendar on Amgen,s website, www.amgen.com , under Investors. ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 2Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 3Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 4Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 5Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 6Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 7Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results 8
(Date:7/28/2014)... CA (PRWEB) July 28, 2014 At some ... uncomfortable situation where they’re forced to contact the authorities. ... more difficult than it initially seems. , Not every dangerous ... vehicle get stolen, a person get mugged, or a bank ... less obvious, leading onlookers to be more passive than they ...
(Date:7/28/2014)... The report “Industrial Enzymes Market by Types (Carbohydrase, ... Bio-Fuel, Animal Feed), & Geography - Global Trends ... global industrial enzymes market with analysis and forecasting ... also identifies driving and restraining factors for the ... opportunities, burning issues, winning imperatives, and challenges. The ...
(Date:7/28/2014)... July 28, 2014 "Fist bumping" transmits significantly ... still addressing the cultural expectation of hand-to-hand contact ... published in the August issue of the ... publication of the Association for Professionals in Infection ... from the Institute of Biological, Environmental, and Rural ...
(Date:7/28/2014)... Qualis Health, one of the ... has published a complimentary, online toolkit that provides ... and families in infection control. Tested and ... toolkit provides a step-by-step roadmap for implementing an ... families early in a hospital stay. , “Across ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Recent research ... desk all day for years can lead to a ... cardiovascular disease. But using a standing desk, or an ... pain, often driving office workers back to a seated ... are designed to alleviate this leg pain and ...
Breaking Medicine News(10 mins):Health News:Take Action To Protect Your Fellow Citizens 2Health News:Take Action To Protect Your Fellow Citizens 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Fist-bumping beats germ-spreading handshake, study reports 2Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:New Standing Desk Anti-fatigue Mats from Martinson-Nicholls Reduce Leg Fatigue and Discomfort Working at Standing and Sit-to-Stand Desks 2
... brain may have problems in forming perception categories for// printed ... to the dyslexics finding it difficult to filter out visual ... of them. ,The research by the scientists from University ... the nature of the workings of a dyslexic brain. ...
... to lose knee lubrication following an injury to the knee. ... University of Rhode Island had identified a way to find ... knee after a knee injury, in order to find out ... ,Although knee injury is considered to be a risk ...
... that children are more exposed to indoor allergens// at ... that are commonly found indoor include bacteria, molds, mildew, ... cockroaches and pollens. These may cause allergic reactions like ... Some of the symptoms experienced by people in presence ...
... survived cancer may have higher risks of having cognitive// ... University of Southern California had found that patients who ... twice as much risk as their healthy counterparts of ... survivors of cancer and their twins with the help ...
... Canada helped in conceiving and// delivering world’s first baby ... mother of the baby had her eggs collected from ... thawed and fertilized from sperms of her partner through ... was implanted in her uterus, which she carried to ...
... constantly exposed to air pollutions of big// cities may ... ,Inhalation of polluted air of the metros can ... particles emitted from the cars, trucks, buses, tobacco smoke, ... the chromosome of the fetus. , ,The research ...
Cached Medicine News:
... I Direct to High Res SSP kits provide high ... tray. Locus specific typing on a single tray reduces ... Straight from genomic DNA to high resolution results, no ... typing with a single tray , Unique reaction pattern ...
... built-in bags as in a suspension file system, ... contacting the ethylene glycol and without having to ... easy handling and maximum surface freezing concurrently with ... relatively hot air under the lid does not ...
... 8624 is UL Listed, CSA ... Plasma Freezers safely store single ... cryoprecipitate. Recorders are standard. Cold ... (12.7cm) of foamed-inplace polyurethane insulation ...
... A small self-contained freezer complying with ... blood plasma. External finish is grey colorbond ... assisted lid opening to a 40-litre capacity ... an effective single gasket contacting a heated ...
Medicine Products: